Test Product HY07121

Phase 2Small molecule

Test Product HY07121 is one of 88 small molecule programs targeting Patients With Advanced Solid Tumors. It is currently in Phase 2.

Indications

Total Trials

Active Trials

Competitors

Pipeline

Status by Indication[3][1]

Indication

Patients With Advanced Solid TumorsRecruiting

Tyrosine Kinase InhibitorsRecruiting

Advanced Solid TumorsRecruiting

Patients With Advanced Solid TumorsPhase 2

Recruiting

Tyrosine Kinase InhibitorsPhase 2

Recruiting

Advanced Solid TumorsPhase 2

Recruiting

Competition

Competitive Landscape

311 competitors in Advanced Solid Tumors

#DrugCompanyPhaseTrials

Opdivo

Bristol-Myers Squibb

Phase 2

19 2

Fludara

Sanofi

Phase 2

16 3

Avastin

Roche

Phase 2

15 4

Paraplatin

AAvyxa

Phase 2

32 5

Abraxane

Bristol-Myers Squibb

Phase 2

11 6

Tecentriq

Roche

Phase 2

11 7

Beyfortus

BeiGene

Phase 2

10 8

Imfinzi

AstraZeneca

Phase 2

10 9

Cytoxan

BBaxter Healthcare Corporation

Lenvima

Ranked by pipeline maturity and clinical activity. Current drug highlighted in teal.

Timeline

Expected Milestones

Q4 2026

Phase 1/2Recruiting

Patients With Advanced Solid Tumors

NCT06639256

Phase 1/2Recruiting

Patients With Advanced Solid Tumors

NCT06243354

Q3 2027

Phase 1/2Recruiting

Advanced Solid Tumors

NCT07069062

Q2 2028

Phase 1/2Recruiting

Tyrosine Kinase Inhibitors

NCT06712680

Clinical

Trials by Indication[1]

Patients With Advanced Solid Tumors2 trials

Phase 1/2 Clinical Study of HY07121 Powder for Solution for Infusion in Patients With Advanced Solid Tumors

Recruiting·SSichuan Huiyu Pharmaceutical Co., Ltd·Phase 1/2·NCT06639256·258 enrolled

Phase 1/2 Study of HYP-2090PTSA in Patients With Advanced Solid Tumors Harboring KRAS Mutation

Recruiting·SSichuan Huiyu Pharmaceutical Co., Ltd·Phase 1/2·NCT06243354·257 enrolled

Tyrosine Kinase Inhibitors1 trial

A Phase I/II Study of HYP-6589 Monotherapy in Treating Advanced Solid Tumors and in Combination With Tyrosine Kinase Inhibitors in Treating Patients With Advanced NSCLC Positive for Driver Genes

Recruiting·SSichuan Huiyu Pharmaceutical Co., Ltd·Phase 1/2·NCT06712680·115 enrolled

Advanced Solid Tumors1 trial

A Phase I/Ⅱ Human Study of HY0001a for Injection in Adult Participants With Advanced Solid Tumors

Recruiting·SSichuan Huiyu Pharmaceutical Co., Ltd·Phase 1/2·NCT07069062·261 enrolled

Sources

References

[1]
ClinicalTrials.gov — 4 trial records for Test Product HY07121. U.S. National Library of Medicine, National Institutes of Health.
[2]
ChEMBL — Test Product HY07121 compound record. European Bioinformatics Institute (EMBL-EBI).
[3]
Open Targets Platform — Drug–disease associations for Test Product HY07121. EMBL-EBI & Wellcome Sanger Institute.
[4]
SEC EDGAR — Sichuan Huiyu Pharmaceutical Co., Ltd company filings. U.S. Securities and Exchange Commission.

Details

Drug Info

Quick Facts

Modality: Small molecule[2]
Highest Phase: Phase 2[1]
Company: SSichuan Huiyu Pharmaceutical Co., Ltd

Test Product HY07121

Status by Indication[3][1]

Competitive Landscape

Expected Milestones

Q4 2026

Q3 2027

Q2 2028

Trials by Indication[1]

Patients With Advanced Solid Tumors2 trials

Tyrosine Kinase Inhibitors1 trial

Advanced Solid Tumors1 trial

References

Drug Info

Quick Facts

Related News